Drug Trial Radar · NCT01095731
The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Apr 2010
Primary completion
Jul 2012
Study completion Jul 2013
Sponsor
- Lead sponsor
- E. Sander ConnollyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Florida; University of Washington; Food and Drug Administration (FDA)
- First posted
- Mar 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
Conditions
- Aneurysmal Subarachnoid Hemorrhage
Interventions
TioproninDrug
Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
PlaceboDrug
Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) LevelsTime frame: Day 7
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Florida
Gainesville, Florida
Columbia University Medical Center
New York, New York
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.